Lysosomal Acid Lipase Deficiency (LAL-D) Treatment Market – By Indication (Wolman Disease [WD], Cholesteryl Ester Storage Disease [CESD]), Treatment Type (ERT, Supportive Care, Lipid Modifying Agents), Global Forecast 2024 – 2032

Report Content

Chapter 1   Methodology & Scope

1.1    Market scope & definitions

1.2    Research design

1.2.1    Research approach

1.2.2    Data collection methods

1.3    Base estimates & calculations

1.3.1    Base year calculation

1.3.2    Key trends for market estimation

1.4    Forecast model

1.5    Primary research and validation

1.5.1    Primary sources

1.5.2    Data mining sources

Chapter 2   Executive Summary

2.1    Industry 360⁰ synopsis

Chapter 3   Industry Insights

3.1    Industry ecosystem analysis

3.2    Industry impact forces

3.2.1    Growth drivers

3.2.1.1    Increasing demand for personalized medicine

3.2.1.2    Advancements in genetic testing

3.2.1.3    Growing awareness for early diagnosis and treatment

3.2.1.4    Rising investments in rare disease research

3.2.2    Industry pitfalls & challenges

3.2.2.1    High cost of the treatment

3.2.2.2    Stringent regulatory requirement

3.3    Growth potential analysis

3.4    Regulatory landscape

3.5    Pipeline analysis

3.6    Porter's analysis

3.7    PESTEL analysis

Chapter 4   Competitive Landscape, 2023

4.1    Introduction

4.2    Company market share analysis

4.3    Company matrix analysis

4.4    Competitive analysis of major market players

4.5    Competitive positioning matrix

4.6    Strategy dashboard

Chapter 5   Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)

5.1    Key trends

5.2    Wolman disease (WD)

5.3    Cholesteryl ester storage disease (CESD)

Chapter 6   Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)

6.1    Key trends

6.2    Enzyme replacement therapy (ERT)

6.3    Supportive care

6.4    Lipid modifying agents

6.5    Other treatment types

Chapter 7   Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)

7.1    Key trends

7.2    North America

7.2.1    U.S.

7.2.2    Canada

7.3    Europe

7.3.1    Germany

7.3.2    UK

7.3.3    France

7.3.4    Spain

7.3.5    Italy

7.3.6    Rest of Europe

7.4    Rest of the World

Chapter 8   Company Profiles

8.1    Alexion Pharmaceuticals

8.2    Amgen Inc.

8.3    AstraZeneca

8.4    BioCrick BioTech

8.5    Lupin

8.6    Merck & Co., Inc.

8.7    Pfizer Inc.

8.8    Regeneron Pharmaceuticals, Inc.

8.9    Teva Pharmaceutical Industries Ltd.

8.10    Thermo Fisher Scientific Inc.

8.11    Zydus Group